Cargando…
Genetically proxied interleukin-6 receptor inhibition: opposing associations with COVID-19 and pneumonia
Respiratory disease is a main feature of severe COVID-19, and the potential of IL-6 receptor blockade to increase risk of pneumonia warrants vigilance and caution in its application to treat COVID-19 https://bit.ly/34Y8Ner
Autores principales: | Larsson, Susanna C., Burgess, Stephen, Gill, Dipender |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Respiratory Society
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7683792/ https://www.ncbi.nlm.nih.gov/pubmed/33214204 http://dx.doi.org/10.1183/13993003.03545-2020 |
Ejemplares similares
-
Interleukin-6 and intrapulmonary shunt
por: Perez-Vizcaino, Francisco, et al.
Publicado: (2021) -
Treatment of severe covid-19 with interleukin 6 receptor inhibition
por: Rajasundaram, Skanda, et al.
Publicado: (2022) -
Pulmonary embolism in patients with COVID-19 pneumonia
por: Bompard, Florian, et al.
Publicado: (2020) -
Genetically Proxied Inhibition of Coagulation Factors and Risk of Cardiovascular Disease: A Mendelian Randomization Study
por: Yuan, Shuai, et al.
Publicado: (2021) -
Remote monitoring of oxygen saturation in individuals with COVID-19 pneumonia
por: O'Carroll, Orla, et al.
Publicado: (2020)